S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:CLDX - Celldex Therapeutics Stock Price, Forecast & News

$2.24
-0.08 (-3.45 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$2.22
Now: $2.24
$2.35
50-Day Range
$2.14
MA: $2.38
$2.79
52-Week Range
$2.01
Now: $2.24
$11.63
Volume78,094 shs
Average Volume280,366 shs
Market Capitalization$36.13 million
P/E RatioN/A
Dividend YieldN/A
Beta3.42
Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CLDX
CUSIP15117B10
Phone908-200-7500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.54 million
Cash Flow$1.74 per share
Book Value$10.78 per share

Profitability

Net Income$-151,180,000.00
Net Margins-1,119.84%

Miscellaneous

Employees133
Market Cap$36.13 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive CLDX News and Ratings via Email

Sign-up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.


Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

When did Celldex Therapeutics' stock split? How did Celldex Therapeutics' stock split work?

Shares of Celldex Therapeutics reverse split on the morning of Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.84) by $0.09. The biopharmaceutical company earned $0.55 million during the quarter, compared to analysts' expectations of $1.26 million. Celldex Therapeutics had a negative return on equity of 43.03% and a negative net margin of 1,119.84%. View Celldex Therapeutics' Earnings History.

When is Celldex Therapeutics' next earnings date?

Celldex Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Celldex Therapeutics.

What price target have analysts set for CLDX?

2 analysts have issued 12 month price objectives for Celldex Therapeutics' stock. Their forecasts range from $19.00 to $19.00. On average, they expect Celldex Therapeutics' stock price to reach $19.00 in the next year. This suggests a possible upside of 748.2% from the stock's current price. View Analyst Price Targets for Celldex Therapeutics.

What is the consensus analysts' recommendation for Celldex Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celldex Therapeutics.

Has Celldex Therapeutics been receiving favorable news coverage?

Media headlines about CLDX stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Celldex Therapeutics earned a daily sentiment score of -1.1 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Celldex Therapeutics.

Who are some of Celldex Therapeutics' key competitors?

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include Opko Health (OPK), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), Corbus Pharmaceuticals (CRBP), Intrexon (XON), Micron Technology (MU), Novavax (NVAX), Dynavax Technologies (DVAX) and Exelixis (EXEL).

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the folowing people:
  • Anthony S. Marucci, President, Chief Executive Officer & Director
  • Sam Martin, CFO, Secretary, Treasurer & Senior Vice President
  • Tibor Keler, Chief Scientific Officer & Executive VP
  • Elizabeth Crowley, Chief Product Development Officer & Senior VP
  • Ronald A. Pepin, Chief Business Officer & Senior Vice President

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.09%). Company insiders that own Celldex Therapeutics stock include James J Marino and Tibor Keler. View Institutional Ownership Trends for Celldex Therapeutics.

Which institutional investors are buying Celldex Therapeutics stock?

CLDX stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Celldex Therapeutics stock in the last two years include James J Marino and Tibor Keler. View Insider Buying and Selling for Celldex Therapeutics.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $2.24.

How big of a company is Celldex Therapeutics?

Celldex Therapeutics has a market capitalization of $36.13 million and generates $9.54 million in revenue each year. The biopharmaceutical company earns $-151,180,000.00 in net income (profit) each year or ($6.82) on an earnings per share basis. Celldex Therapeutics employs 133 workers across the globe.View Additional Information About Celldex Therapeutics.

What is Celldex Therapeutics' official website?

The official website for Celldex Therapeutics is http://www.celldex.com/.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]


MarketBeat Community Rating for Celldex Therapeutics (NASDAQ CLDX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  535 (Vote Outperform)
Underperform Votes:  323 (Vote Underperform)
Total Votes:  858
MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe CLDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel